Navigation Links
Epstein-Barr virus protein crucial to its role in blood cancers

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers. Their findings demonstrate a new mechanism by which EBV transforms human B cells from the immune system into cancerous cells, which can lead to development of B-cell lymphomas.

Erle S. Robertson, PhD, Associate Professor of Microbiology and Director of Tumor Virology, with Penn's Abramson Cancer Center and MD/PhD student Jason Knight, published their results in the early March issue of Molecular and Cellular Biology.

Using human cell cultures infected with the Epstein-Barr virus, the investigators found that a specific viral protein targets a molecule that normally regulates the cell-cycle progression, or duplication process, of resting B cells. In the presence of this viral protein ?called EBNA3C (for EBV nuclear antigen) ?the cell cycle of the usually quiescent human B cells gets a jump start, which ultimately initiates uncontrolled growth.

EBV, a member of the herpesvirus family and one of the most common human viruses, plays a role in cancers such as lymphoproliferative diseases in transplant or AIDS patients, Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma, and also causes the well-known disease, infectious mononucleosis. As many as 95 percent of adults 20 years and older have been infected with EBV, but show no symptoms.

"Viruses that are associated with cancers typically target the cell cycle to gain control," says Robertson. "However, this is the first time that laboratory research into how EBV drives the cancer process has directly identified a critical component of the cell cycle for control. Now we can develop targeted therapeutics to disrupt the function of this viral protein." The researchers surmise that the first use of future therapies from these studies will be in lymphoprolifera tive disease in transplant and immunocompromised patients because this is a clear case of EBV-driven B-cell lymphoma.

The use of peptides to block the interaction between this essential EBV protein and the specific pathway in human B cells is currently underway. Initial studies show that the growth of EBV-associated cancer cells can be inhibited in tissue-culture assays. The investigators are actively pursuing this line of investigation for developing potential therapies.


'"/>

Source:University of Pennsylvania Medical Center


Related biology news :

1. U of T researchers map role of Epstein-Barr virus in cancer
2. Mechanism for Epstein-Barr virus proteins role in blood cancers discovered
3. Epstein-Barr virus may be associated with multiple sclerosis
4. Epstein-Barr virus might kick-start multiple sclerosis
5. Clue found to Epstein-Barr virus ability to form and sustain tumors
6. Association of herpesvirus with lung disorder questioned
7. Topical treatment shown to inhibit HIV and herpes simplex virus infection
8. Elusive HIV shape change revealed; Key clue to how virus infects cells
9. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
10. Live Recombinant Adenovirus Vaccine Technique Explored
11. Marburg virus disease in Angola - update
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... 2017 , ... BellBrook Labs is formalizing a significant expansion ... biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services will ... inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on drug ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... , ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC ... GGI's mission is to advance global health and highlight the greater good of clinical ... each clinical trial volunteer. The vision of GGI is to serve as a philanthropic ...
(Date:2/22/2017)... 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet ... innovative biopharmaceutical products for companion animals, will host a live ... ET to discuss financial results from the fourth quarter and ... participants and investors may access the audio webcast ... ...
Breaking Biology Technology: